Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations

[1]  Z. Zhao,et al.  Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China , 2022, Advances in Therapy.

[2]  Rui Meng,et al.  Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma , 2022, Expert review of pharmacoeconomics & outcomes research.

[3]  Wenxi Tang,et al.  Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis , 2022, Frontiers in Public Health.

[4]  C. Bergelt,et al.  The impact of cancer on the mental health of patients parenting minor children: A systematic review of quantitative evidence , 2022, Psycho-oncology.

[5]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations , 2022, BMJ.

[6]  J. Pilz,et al.  Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb , 2021, Hospital pharmacy.

[7]  P. Petrou,et al.  Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review , 2021, Molecular Diagnosis & Therapy.

[8]  T. Mattingly,et al.  A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment , 2021, PharmacoEconomics - Open.

[9]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[10]  A. Vogel,et al.  The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective , 2021, Canadian journal of gastroenterology & hepatology.

[11]  Lizheng Shi,et al.  Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma , 2021, JAMA network open.

[12]  M. Kudo,et al.  Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. , 2021, Value in health regional issues.

[13]  P. Scuffham,et al.  Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia , 2020, Clinical Drug Investigation.

[14]  K. Attwood,et al.  Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis , 2020, Liver Cancer.

[15]  M. Pinter,et al.  Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups , 2020, Gut.

[16]  S. Ronnebaum,et al.  Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review , 2020, Hepatic oncology.

[17]  Maobai Liu,et al.  Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. , 2020, Journal of comparative effectiveness research.

[18]  C. Bokemeyer,et al.  Prevalence and Predictors of Distress, Anxiety, Depression, and Quality of Life in Bereaved Family Caregivers of Patients With Advanced Cancer , 2020, The American journal of hospice & palliative care.

[19]  John J Kim,et al.  Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. , 2019, The oncologist.

[20]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[21]  Kehua Zhou,et al.  Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma , 2019, Cancers.

[22]  Z. Younossi,et al.  Disease Burden of Hepatocellular Carcinoma: A Global Perspective , 2019, Digestive Diseases and Sciences.

[23]  J. Bruix,et al.  Controversies in the management of hepatocellular carcinoma , 2019, JHEP reports.

[24]  M. Kudo,et al.  Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan , 2019, Journal of Gastroenterology.

[25]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[26]  A. Zhu,et al.  Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. , 2016, Immunotherapy.

[27]  Amit G Singal,et al.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[29]  I. Popescu.  Hepatocellular carcinoma – new trends , 2010 .

[30]  M. Omata,et al.  Hepatocellular carcinoma in viral hepatitis: improving standard therapy. , 2008, Best practice & research. Clinical gastroenterology.